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Background: Nonpalpable breast lesions require localization, the gold standard for which is preoperative
ultrasound-guided wire localization (PUGWL). Our unit also employs intraoperative ultrasound-guided
wire localization (IUGWL). Here we evaluate PUGWL and IUGWL outcomes between 2014 and 2018. Pri-
mary outcomes were reoperation rates, complication rates and average specimen weights. Trainee feed-
back and cost analysis assessed IUGWL viability. Methods: Prospectively recorded data were collected. 511
patients were included (241 PUGWL and 270 IUGWL). Results: Reoperation rates: PUGWL 17.7% versus
IUGWL 13.9% (p = 0.28). Complication rates: PUGWL 5.8% versus IUGWL 6.6% (p = 0.72). Average spec-
imen weight: PUGWL 34.2 g versus IUGWL 24.3 g (p < 0.0001). Trainees needed 15 supervised cases to
be IUGWL competent. Performing IUGWL saves £289 per localization. Conclusion: IUGWL outcomes are
comparable to those of PUGWL. IUGWL is cost-effective, patient-friendly and easy to learn and replicate.
IUGWL merits wider dissemination and further planned research.
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Background
In 2017–18 the UK National Health Service Breast Cancer Screening Programme screened 2.14 million women,
detecting over 18,000 breast cancers. 40.1% of these patients had small invasive cancers [1].
Our tertiary breast cancer unit treats around 500 cancers annually, 40% of which are screen detected. The vast
majority of screen-detected lesions are nonpalpable lesions (NPL). Patients with partial or complete response to
neoadjuvant therapy add to the number of NPLs treated.
NPLs require localization for breast-conserving surgery (BCS). Traditionally this is performed preoperatively by
a Radiologist, using image guidance placing a guidewire into the lesion under local anesthetic. A mammogram
then confirms guidewire placement.
Most lesions are ultrasound visible and this is the most commonly used imaging technique for guidewire local-
ization [2–4]; it is faster than stereotactic guidance, and easily operated. Calcification and disease not sonographically
visualized can be made localizable using a device often referred to as a marker clip [5,6]. The marker clip is placed in
the center of the lesion at diagnostic biopsy. Further mammographic imaging ascertains if it is correctly positioned
prior to localization. Patients undergoing neoadjuvant treatment have one or more marker clips deployed prior
to commencing systemic treatment. The position of the marker clip, the size of the lesion and the relationship
between the two are reassessed with ultrasound prior to surgery [7].
Patients having BCS for a NPL are kept busy on the day of surgery with trips to nuclear medicine, radiology and
finally the operating theatre. They also potentially have two invasive procedures: ultrasound-guided localization
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with subsequent mammography and nuclear medicine injection for sentinel lymph node biopsy. This adds to the
patient’s anxiety, stress and physical discomfort.
A preoperative ultrasound-guided wire localization (PUGWL) is a costly technique requiring complex organi-
zational arrangements around scarce resources in radiology departments. From a surgeon’s perspective, guidewires
carry the risk of displacement and migration [8–11] and may take a tortuous route through the breast, increasing the
difficulty of BCS. Alternative isotope-based techniques for excision of NPLs, such as radio occult lesion localization
or radioactive seeds, carry their own organizational difficulties and are increasingly difficult to implement due to
regulations surrounding isotope use. Techniques such as magnetic seeds or radiofrequency transponder devices
overcome some of these difficulties but require dedicated equipment and are usually priced to match the cost of a
preoperative localization. All intraoperative localization techniques require additional training.
Ultrasound devices are used in multiple clinical settings and are increasingly readily available in many operating
theatres. Demonstration of a known breast lesion is a basic function of breast ultrasound and can be employed
intraoperatively to localize a NPL or marker clip [12–17]. While ultrasound alone can be used to locate a lesion, the
addition of a guidewire provides haptic feedback when NPLs are being excised, increasing confidence in excision,
saving time and minimizing the extent of resection.
Intraoperative ultrasound-guided wire localization (IUGWL) of NPLs was introduced into our unit after initial
evaluation. Here we report on the outcomes of this technique in comparison with the gold standard PUGWL.
Aim
To evaluate the surgical and oncological outcomes and viability of the IUGWL technique.
Primary outcomes
Reoperation rates, resection size as assessed by specimen weights and surgical complications in IUGWL and
PUGWL.
Secondary outcomes
To assess the accuracy and precision of localization and specimen excision in both groups using specimen x-rays. To
evaluate the learning curve for the IUGWL technique as part of the surgical training program. To evaluate the effect
on operating theatre time of the IUGWL technique. To assess the cost–effectiveness of the IUGWL technique.
Patients & methods
Subject identification & data collection
We used an opportunistic study design using a convenient sample of routinely collected data from patients being
managed for breast cancer at our institution.
Data between October 2014 and December 2018 were collected from the electronic records system EPIC R©.
Anonymized data were recorded and analyzed. Proportions were analyzed using Fisher’s exact test, and means using
Student’s t test with Prism software (GraphPad, CA, USA); p-values <0.05 were statistically significant.
Consecutive cases between October 2014 and December 2018 were included in the study if they fulfilled all the
following inclusion and exclusion criteria.
Inclusion criteria
Patients with documented NPL.
Patients with core biopsy-confirmed invasive cancer or high grade ductal carcinoma in situ treated with BCS.
Patients with NPL and a sonographically visible lesion or marker clip that could be localized using ultrasound
guidance.
Patients who underwent PUGWL or IUGWL for BCS.
Patients who had an intraoperative specimen radiograph taken.
Exclusion criteria
Patients undergoing diagnostic excision biopsies for benign or indeterminate lesions.
Patients undergoing therapeutic mammoplasties as BCS using either PUGWL or IUGWL.
Patients who underwent a combination of PUGWL and IUGWL for BCS.
Patients who underwent stereotactic guided wire localizations for NPL.
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Table 1. Criteria for assessing the accuracy of localization and quality of the specimen excision.
Score Localization accuracy Lesion centricity in
specimen
1 Hook of wire within
20 mm of target
NPL or marker clip central
and 5–20 mm from edges
of excision
2 Hook of wire within
20–30 mm of target
NPL or marker clip
eccentric or more than
20 mm from one edge
3 Hook of wire 30 mm
from target
NPL or marker clip looks




Primary outcomes were reoperation rates, specimen weights and surgical complications.
Reoperation rates were established using the number of patients in each group who either underwent re-excision
or proceeded to mastectomy following BSC with positive margins.
Total specimen weight per resection was calculated, including any cavity shaves. Specimen weight is an accurate
surrogate for volume [18]. If a patient had more than one lesion excised in separate specimens, each specimen was
treated as a separate resection.
Surgical complications were any of the following: wound infection, hematoma, seroma, wound dehiscence, skin
necrosis requiring further intervention or treatment. Follow-up was 10–48 months. The fully electronic patient
records system EPIC R© was used to identify complications.
Secondary outcomes
Accuracy & precision of localization & specimen excision
To assess the accuracy and precision of localization and specimen excision, two surgeons and one radiologist
individually measured pre-agreed parameters, based on Quality Assurance Guidelines for Surgeons in Breast
Cancer Screening [19] for anonymized specimen x-rays, and assigned a score as set out in Table 1. The closer to 1
the score, the more accurate the localization and the more centralized the lesion in the excision. Patients with more
than one lesion had each lesion scored separately. A proportion of sequential patients were included in this part of
the study, excluding those with no identifiable lesion or no guidewire on the specimen x-ray.
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Viability of IUGWL in training surgeons
To evaluate the learning curve for IUGWL, three senior breast trainees were given one-to-one training by a consultant
surgeon. Once deemed competent, the trainees performed IUGWL independently. Training was evaluated with a
questionnaire.
Evaluating the effect of IUGWL on operating theatre time
The electronic records system is updated in real time in the operating theatre. Events are recorded as: time into
theatre, anesthetic start time, anesthetic ready time, knife to skin, operation finish time and time out of theatre.
Assessment of surgical time was confined to patients undergoing excision of a single breast lesion either by PUGWL
or with IUGWL. Anesthetic ready time to operation finish time was collected and analyzed.
Assessing the cost–effectiveness of IUGWL
The costing team in the hospital’s finance department was asked to provide the breakdown and total cost of each
procedure.
PUGWL method
PUGWLs are performed by a Radiologist on the day of surgery under local anesthetic in the Radiology department
of the Breast Unit. The wire is dressed, and a two-view post-localization mammogram performed and reported.
This entire process takes a minimum of 25 min per patient.
IUGWL method
IUGWLs are performed by the surgeon in the operating theatre. Once the patient is under general anesthesia,
prepped and draped, the guidewire is inserted under ultrasound guidance. A post-wire mammogram is not
required. No additional operating time is allotted for scheduling IUGWL cases.
A Sonosite Edge R© (Amsterdam, Netherlands) ultrasound with a 15-6 MHz linear array probe is used to identify
the target (either the lesion or a marker clip) in multiple planes. Our unit uses Hydromark R© (Cincinnati, OH,
USA) as a marker clip. We initially used a hook guidewire, but recently we have changed to an anchor guidewire
which can be introduced one-handed: the Tuloc Premium, Somatex R© (Berlin, Germany). An intraoperative
specimen radiograph is taken to assess margins.
Results
511 patients were included in this study. 241 patients had PUGWL for 258 lesions, and 270 patients had IUGWL
for 280 lesions.
Patient & tumor characteristics
All patients were female. The median age for PUGWL was 63 years (range: 29–86) and median age for IUGWL was
60 years (range: 21–86). 12% of patients in the PUGWL group were current smokers, compared with 9% in the
IUGWL group. 69% of patients in the PUGWL group and 68% in the IUGWL group had recorded comorbidities.
97% of PUGWL patients and 96% of IUGWL patients were from a white European ethnic background. There
was no significant different between PUGWL and IUGWL with regards to mean size of each index lesion (mm)
targeted, patients with sonographic masses or type of disease (Table 2).
Primary outcomes
Primary outcomes for all cases included in this study are shown in Table 3.
Analysis of patients treated with primary surgery
Table 4 shows primary outcomes and tumour characteristics of patients treated with primary surgery.
Analysis of patients treated with neoadjuvant therapies
Table 5 shows the primary outcomes and tumour characteristics for patients who underwent neoadjuvant treatment.
Analysis of high grade ductal carcinoma in situ
Patients with high-grade ductal carcinoma in situ (DCIS) alone in the PUGWL group had an average lesion size on
histology of 16 mm, versus 17.5 mm in the IUGWL group. The re-excision rate in the PUGWL group was 13/31
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Table 2. Tumor characteristics for all patients included in this study.
PUGWL IUGWL Total p-value
Total number of patients 241 270 511
Number of resections 248 273 521
Number of lesions 258 280 538
Patients with multifocal disease 16/241 (7%) 10/270 (4%) 26/511 (5%) ns
Patients with sonographic mass 191/241 (79%) 213/270 (79%) 404/511 (79%) ns
Patients who underwent neoadjuvant therapy 32/241 (13%) 62/270 (23%) 94/511 (18%) ns
Invasive cancer +/− in situ component 217/248 (88%) 232/273 (85%) 449/521 (86%) ns
Carcinoma in situ (high-grade DCIS) 31/248 (12%) 41/273 (15%) 71/521 (14%) ns
Mean lesion size on histology (mm) 12.1 (0–47) 11.8 (0–50) ns
Invasive cancer Grade 1, 2, 3, ungradable 61, 116, 39, 1 49, 114, 69, 0 0.01
Nodal status positive 26/217 33/232 ns
DCIS: Ductal carcinoma in situ; IUGWL: Intraoperative ultrasound-guided wire localization; ns: Not significant; PUGWL: Preoperative ultrasound-guided wire localization.
Table 3. Primary outcomes of all preoperative versus intraoperative ultrasound-guided wire localization patients.
PUGWL IUGWL p-value
Mean specimen weight per resection (g) 34.2 (range: 3.7–155) 24.3 (range: 3.1–176) 0.0001
Complication rate 14/241 (5.8%) 18/270 (6.6%) 0.72
Reoperation rate 44/248 (17.7%) 38/273 (13.9%) 0.28
There was a significant difference between the mean specimen weights per resection in each group: the IUGWL group had lower specimen weights. There was no significant
difference in the reoperation rate or complication rate.
IUGWL: Intraoperative ultrasound-guided wire localization; PUGWL: Preoperative ultrasound-guided wire localization.
Table 4. Analysis of all patients in preoperative and intraoperative ultrasound-guided wire localization groups
who had primary surgery.
PUGWL IUGWL p-value
Total number of patients 209 208
Median age (years) 65 (range: 29–86) 61 (range: 37–86) ns
Number of lesions 224 216
Number of resections 215 211
Mean specimen weight per resection (g) 34.2 (range: 4.9–130) 22.8 (range: 3.1–105.3) 0.0001
Complication rate 10/209 (4.9%) 12/208 (5.7%) ns
Reoperation rate 41/215 (19%) 35/211 (16.5%) ns
Mean lesion size on histology (mm) 13.1 (range: 1–47) 12.9 (range: 1.5–40) ns
Invasive cancer grade 1, 2, 3 61, 101, 22 48, 96, 26 ns
Nodal status positive 23/184 21/170 ns
High grade DCIS 31/215 41/211
There was a significant difference in the specimen weights between PUGWL and IUGWL patients. IUGWL patients had a smaller average specimen weight. There were no
significant differences in any of the other outcomes.
DCIS: Ductal carcinoma in situ; IUGWL: Intraoperative ultrasound-guided wire localization; ns: Not significant; PUGWL: Preoperative ultrasound-guided wire localization.
(42%) and in the IUGWL group 7/41 (17.5%) (p = 0.03). The average weight of the resection in the PUGWL
group was 32.9 g and in the IUGWL group was 20.5 g (p = 0.01).
Secondary outcomes
To assess quality measures, learning curve, cost effectiveness and effect on operating theatre time of IUGWL
compared to PUGWL.
Quality measures of localization & excision
A total of 334 patients (171 PUGWL and 163 IUGWL) were included in this analysis (Table 6).
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Table 5. Primary outcomes for patients who underwent neoadjuvant treatment.
PUGWL IUGWL p-value
Total number of patients 32 62
Number of lesions 34 64
Number of resections 33 62
Median age (years) 55 (range: 29–69) 54 (range: 21–77)
Mean specimen weight per resection (g) 33.9 (range: 3.7–155) 29.4 (range: 4–176) ns
Complication rate 4/32 (12.5%) 6/62 (9.7%) ns
Reoperation rate 3/33 (9%) 3/62 (4.8%) ns
Mean size per lesion on histology (mm) 5.5 (range: 0–27) 7.9 (range: 0–50) ns
Invasive cancer grade 1, 2, 3, unable to grade 2, 13, 17, 1 1, 19, 42, 0
Nodal status positive 3/33 12/62
There was no significant difference in the average specimen weight, reoperation rate or complication rate between the two groups for patients who underwent neoadjuvant
treatment.
IUGWL: Intraoperative ultrasound-guided wire localization; ns: Not significant; PUGWL: Preoperative ultrasound-guided wire localization.
Table 6. Accuracy of preoperative versus intraoperative ultrasound-guided wire localization.
Localization accuracy PUGWL (n = 167) IUGWL (n = 161)
1 = High level of accuracy 140 (84%) 137 (85%)
2 = Medium level of accuracy 18 (11%) 17 (11%)
3 = Low level of accuracy 9 (5%) 7 (4%)
Lesion centricity in specimen PUGWL (n = 171) IUGWL (n = 163)
1 = Lesion central 78 (45%) 89 (55%)
2 = Lesion slightly eccentric 61 (36%) 55 (34%)
3 = Lesion eccentric or transected 32 (19%) 19 (11%)
Values for accuracy and specimen excision quality should be as close to 1 as possible. The two groups have similar results in both categories.
IUGWL: Intraoperative ultrasound-guided wire localization; PUGWL: Preoperative ultrasound-guided wire localization.
IUGWL effect on operating time
To establish whether using IUGWL has any effect on operating times, 175 patients in each group having excision
of a single lesion were identified. Data recorded in real time for anesthetic ready time and operation finish time
were collected and analyzed. The PUGWL group had a mean operating time of 85 min, while the IUGWL group
had a mean operating time of 78 min (p = 0.002).
Trainees evaluation of learning curve
The three senior surgical trainees reported that they were able to perform the IUGWL procedure independently
after 15 proctored insertions, taking a maximum of 5 minutes per procedure. There were no misplaced wires
or wire-related complications during the training phase or afterward. All three trainees reported that they will
incorporate the technique into their consultant practice. They would also recommend the technique to other
trainees and feel competent to teach the technique.
Cost–effectiveness of IUGWL
PUGWL costs £326 per procedure, including the cost of a post-localization mammogram.
IUGWL adds no operating theatre time. The additional disposables (guidewire plus sterile ultrasound probe
cover) cost £37 per case. This represents a cost saving of £289 per case, or £80,920 for the 280 NPLs excised using
IUGWL in this study.
The use of IUGWL also frees approximately 25 min of radiology time per case.
Discussion
Techniques for dealing with NPLs have been discussed since 1966 [20]. Over time, the National Health Service
Breast Cancer Screening Programme and neoadjuvant therapies have established NPLs as a regular feature on
operating theatre lists. Preoperative wire localizations became the gold standard for excision of NPLs, with many
surgeons adapting to the technique and demonstrating good results [21–24]. The drawbacks are discomfort and stress
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for the patient [25], impact on list planning and breast clinic, pressure on radiology services and potential for wire
migration. IUGWL obviates these issues.
Ultrasound was introduced into preoperative wire localizations in the early 1990s [26]. By the turn of the
century intraoperative ultrasound was being explored by many. Initially a tool for simple identification of NPLs
intraoperatively, its role was extended to assessing resections and cavities to ensure clear margins. Many studies on
intraoperative ultrasound without the use of wires show good results with good rates of clear margins. They also
testified to the ease of learning breast ultrasound [27–33].
The scope of intraoperative ultrasound has widened with the use of hydrogel marker clips which made NPLs not
normally visible on ultrasound sonographically localizable, thus allowing pathology such as high grade DCIS to be
managed with IUGWL.
The use of intraoperative ultrasound combined with surgeon-performed wire localization intraoperatively has
only been mentioned in a few studies. Previous studies have reported that intraoperative ultrasound localization
using a guidewire or marking needle is a safe technique for NPLs, with good outcomes [34–36]. Our study reports
outcomes for the largest number of patients (511 compared with the 214, 28 and 32 from the previous similar
studies). Two of the three previous studies focused only on NPLs, as does ours. Shin et al. reported a total of 214
patients, including only those with invasive cancer with or without associated DCIS [34]. Our cohort of patients
includes those with only invasive cancer, only high-grade ductal carcinoma in situ and mixed disease. Our study
shows favorable re-excision rates and specimen weights with the use of IUGWL for patients with high-grade DCIS
alone when compared with PUGWL.
Ultrasound can be used to image the target before and after the wound is open without the use of a guidewire.
Indeed, some NPLs can be palpable after initial dissection. Many NPLs, however, remain impalpable after initial
dissection. This is particularly the case in NPLs marked with a marker clip, which can be lost during surgery. A
skin marker alone, however, is not as helpful as using a guidewire [37].
The haptic feedback from the wire helps orientate the surgeon once the wound is open and tissue mobilized,
especially in high-volume less dense breasts. The wire assists in centralizing the lesion in the specimen. Repeated
ultrasound inside the wound can be time-consuming. The newer wires allow for a one-handed localization tech-
nique to deploy and anchor the wire, with a much-reduced risk of accidental dislodgement. The presence of a
guidewire can increase confidence in excision, particularly in the event of loss of a marker clip. By placing the
guidewire intraoperatively the surgeon is not limited or constrained in their incision or resection as they may be
with PUGWL.
Our study used an opportunistic study design aimed at evaluating the safety and applicability of a technical
innovation, by comparing it with a conventional technique. Such a design has inherent limitations, and the study is
not intended to provide proof of noninferiority. However, the sample is one of the largest for this type of study
reported in the literature, and the results for the IUGWL group are highly reassuring and should encourage others
to evaluate the technique in other institutions and settings.
The patients in this study were allocated to either IUGWL or PUGWL according to which operating lists
they were assigned to and who they saw in clinic. However, the patient groups had similar characteristics and
disease profiles. While patients for primary surgery are assigned to the next available lists, neoadjuvant patients are
referred to particular surgeons, and this may have resulted in a greater preponderance of patients operated on after
neoadjuvant chemotherapy in the IUGWL group (accounting for the greater number of grade 3 cancers in this
group). However, when the primary surgery and neoadjuvant groups were analyzed separately (Tables 4 & 5), the
outcomes were similar for each subgroup. All operations in the IUGWL group were carried out by or supervised
by one consultant; however, all were treated according to similar protocols, and all decisions regarding treatment
were made by a multidisciplinary team.
Smaller excisions correlate with improved quality of life measures [38]. The IUGWL group had statistically
significantly lower specimen weights without increased reoperation rates. Despite the time required for intraoperative
guidewire insertion, the IUGWL operations took approximately 10% less time. We suggest that IUGWL affords
the surgeon more confidence in their resection and the centricity of the lesion in the specimen and allows the
surgeon to complete the resection more easily, as reflected in reduced operating time. The accuracy of localizations
and excision, as assessed by specimen radiographs, were equally good between the two groups.
The viability of any new surgical technique depends on the transferability of skills. We assessed the training needs
in IUGWL and found that trainees feel competent to perform the procedure independently after 15 supervised
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attempts. There is good concordance in the trainee feedback, and we plan to extend the trainee evaluation of this
study.
The Royal College of Radiologists workforce consensus report in 2018 [39] explains the shortfall in radiologists
across the UK, with many hospital trusts struggling to fill the gaps. The pressure on radiology departments
throughout the UK continues to mount and is projected to get worse over the next 5 years. Solutions like IUGWL
have been welcomed in our department, bringing benefits to both the multidisciplinary team and the patients. We
estimate that our unit has saved £80,920 using this technique between October 2014 and December 2018.
During the COVID-19 pandemic, limiting patient and clinician exposure to what is deemed essential has been
part of the strategy to prevent the spread of the virus. The use of the IUGWL technique has proven particularly
useful for our unit and our patients during this period. Patients post-chemotherapy and others with NPLs have
continued to have surgery during the pandemic.
Not only does the use of IUGWL decrease the footfall across the hospital and reduce exposure for patients and
staff, but it has also allowed us to continue operating on patients with NPLs off the main hospital site without having
to transfer radiological support. It allows flexibility with operating theatre planning, including evening and weekend
elective lists, when departments such as radiology are running on an emergency-only schedule. The use of IUGWL
for suitable cases has allowed patients in this highly anxious time to have one less trip to hospital, avoiding close
interaction with additional personnel (radiologists, radiographers, support staff ) and reducing potential exposure
to COVID-19 during times of national lockdown. Given the guidance from the Association of Breast Surgeons for
the COVID-19 pandemic, many patients were started on primary endocrine treatment and operated on months
later, some with good response and palpable lesions becoming NPLs [40]. Again, the benefit of IUGWL gave us
a ‘safety blanket’ to be able to use ultrasound and localize the lesion if required in the operating theatre on a site
without breast radiologists.
Conclusion
Our study supports the assertion that IUGWL performed by a surgeon is a safe and effective technical innovation in
dealing with nonpalpable breast lesions. The technique is cost-effective and the skills required are easily transferable.
It merits further dissemination and evaluation.
Future perspective
Nonpalpable lesions are very common in our clinical practice and are expected to increase within the next 5–10 years
considering the ever increasing technological advancements in imaging and screening techniques. New imaging
modalities have been under investigation for risk stratification screening such as contrast enhanced mammography,
automated whole breast ultrasound and abbreviated MRIs, which are proven to have higher diagnostic accuracy
and cancer detection rate than the conventional full field digital mammography (FFDM). To establish the ideal
technique for localization of NPLs, future studies should focus on a technique that would minimize patient
exposure and appointments, prevents or minimize distress and anxiety to the patient. The ideal technique allows
flexibility in scheduling, allows the surgeon to feel confident in identifying the position of the nonpalpable lesion,
enables the surgeon to excise the lesion with clear margins and conserve as much breast tissue as possible, allows
the surgeon the freedom to place their incision and resect the lesion whichever way they think would provide the
best outcome. All whilst being cost-effective and easy to learn and implement. There is continuing innovation
in localization techniques for nonpalpable breast lesions such as 3D printing, radioactive seeds, magnetic seeds,
carbon marking, radiofrequency identified tags, radioguided occult lesion localization, IUGWL, intraoperative
ultrasound localization and indocyanine green. The trend is to move away from preoperative localization and likely
to be replaced by one of the newer techniques with time and research. This may however be limited by the cost–
effectiveness, learning curve and ease of implementation of these various techniques in individual units. Individual
units are likely to adopt varying techniques. Ultrasound is already an easily learnt and universally available imaging
technique and the skills required to use it intraoperatively require minimal training to learn. As different techniques
evolve, it is likely we would resort to a transferable technique which can be used in any breast unit regardless of
where the initial biopsy took place. In future, surgical trainees would benefit from training in breast ultrasound and
IUGWL techniques to aid their surgical practice as it is a cost-effective, efficient and accurate method of localization
as demonstrated in our study.
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Summary points
Background
• Nonpalpable breast cancers are common and require localization in order to surgically excise them.
• Various techniques for localization are available, the gold standard is preoperative ultrasound-guided wire
localization (PUGWL).
• An alternative technique employed by our unit is intraoperative ultrasound-guided wire localization (IUGWL).
• IUGWL has many advantages for the patient, surgeon and the breast unit, including freedom in list
scheduling, creative freedom for the surgical incision, confidence for the surgeon in their excision, prevents
stress and discomfort for the patient whilst awake. IUGWL frees up resources such as radiology time and saves the
patient having further mammograms.
• IUGWL has a learning curve and needs adequate training in intraoperative ultrasound and localization.
Aims
• This study aims to assess the viability of the IUGWL technique.
• Here we assess the primary outcomes; re-operation rate, specimen weights and complication rate, and the
secondary outcomes; accuracy and precision of localization and specimen excision, viability of IUGWL in training
surgeons, evaluate the effect of IUGWL on operating theatre time and assess the cost–effectiveness of IUGWL.
Patients & methods
• Patients who underwent either PUGWL or IUGWL from October 2014 to December 2018 were included.
• Patients included were those with a nonpalpable invasive breast cancer or high grade ductal carcinoma in situ
(DCIS) with a visible marker clip or lesion on ultrasound who underwent breast conservation surgery.
• Patient’s who were excluded were those who had a benign or indeterminate lesion at core biopsy, those who had
a combination of PUGWL and IUGWL, those who required a stereotactic guidewire localization and those who
had a therapeutic mammoplasty.
• Data was collected from the electronic records system and analyzed using Prism software.
• A cost analysis of each procedure was conducted.
• Three senior surgical trainees evaluated their experience with the procedure and their cases were assessed for
complications of localizations.
• To assess the impact of IUGWL on theatre operating time, real time data of anaesthetic ready time and
operation finish time for comparable single lesion IUGWL and PUGWL cases were collected and analyzed.
Results
• 511 patients were included in this study. A total of 241 patients had PUGWL for 258 lesions, and 270 patients had
IUGWL for 280 lesions.
• Overall there was a significant difference between the mean specimen weights per resection in each group: the
IUGWL group had lower specimen weights. There was no significant difference in the reoperation rate or
complication rate.
• We analyzed patients who had primary surgery and neoadjuvant treatment separately.
• In those patients who had primary surgery there was a significant difference in the specimen weights between
PUGWL and IUGWL patients. IUGWL patients had a smaller average specimen weight. There were no significant
differences in any of the other outcomes.
• In those patients who had neoadjuvant treatment there was no significant difference in the average specimen
weight, reoperation rate or complication rate between the two groups for patients.
• To assess the accuracy and precision of localization and specimen excision in the PUGWL and IUGWL groups, a
total of 334 patients’ specimen x-rays (171 PUGWL, 163 IUGWL) were scored using specific criteria by two
surgeons and one radiologist.
• IUGWL and PUGWL groups have similar results in both categories used to assess quality of localization and of
excision.
• Comparing operating times in patients undergoing PUGWL versus IUGWL we found PUGWL group had a mean
operating time of 85 min, while the IUGWL group had a mean operating time of 78 min (p = 0.002).
• Trainees evaluation of learning curve revealed that three senior trainees felt competent performing IUGWL after
15 proctored cases. They reported their intention to employ IUGWL in their consultant practice and felt confident
to train others.
• Assessing the costs for each procedure found that using IUGWL saves £289 per case, or £80,920 for the 280 NPLs
excised using IUGWL in this study. The use of IUGWL also frees approximately 25 min of radiology time per case.
Discussion
• Localization techniques for NPLs have been discussed since 1966.
• PUGWL is the current gold standard for localization but it has its draw backs and risks of complications.
• The use of intraoperative ultrasound has increased, with many studies exploring this technique.
• The use of intraoperative ultrasound combined with surgeon-performed wire localization intraoperatively has
only been mentioned in a few studies.
• Our study focuses on invasive cancer with or without an in situ component as well as high grade DCIS.
Conclusion
• Our study supports the use of IUGWL in NPL. IUGWL is safe, cost effective with comparable re-operation rates
and complication rates to PUGWL.
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